{"id":"W2753432434","doi":"10.1056/nejmoa1709684","title":"Overall Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma","year":2017,"lang":"en","type":"article","venue":"New England Journal of Medicine","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":5392,"is_retracted":false,"has_abstract":true,"ca_institutions":"Princess Margaret Cancer Centre","funders":"National Cancer Institute","keywords":"Ipilimumab; Nivolumab; Medicine; Melanoma; Oncology; Internal medicine; Overall survival; Metastatic melanoma; Clinical trial; Immunotherapy; Cancer; Cancer research","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001491288,0.0006851782,0.001466082,0.0005527525,0.0002262609,0.0004320903,0.0004825973,0.0004959525,0.001844862],"category_scores_gemma":[0.0009108472,0.0002007372,0.001052765,0.0003290074,0.0005525482,0.0004197545,0.0004908129,0.001305697,0.0002277046],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.000643428,"about_ca_system_score_gemma":0.0005937549,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0003830998,"about_ca_topic_score_gemma":0.0009185041,"domain_scores_codex":[0.9994652,0.0002600507,0.00003444933,0.00008593802,0.00006171752,0.00009269529],"domain_scores_gemma":[0.9995162,0.0001280846,0.00008700956,0.00004991581,0.00002377707,0.0001949791],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.6335706,0.01727054,0.01750996,0.001045628,0.00263834,0.0001881588,0.0001712408,0.009986844,0.04056438,0.000252505,0.001306165,0.2754956],"study_design_scores_gemma":[0.1948547,0.7104626,0.07014928,0.0001994197,0.003351359,0.0003749568,0.00005093975,0.00617767,0.009448806,0.000811435,0.004066079,0.0000527357],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9946285,0.003732098,0.0003595563,0.0001940817,0.00008151899,0.0001656206,0.0001033688,0.00003146376,0.0007038615],"genre_scores_gemma":[0.9977387,0.000962851,0.0004030123,0.0001240049,0.000088739,0.0002432515,0.0001488571,0.00000598703,0.0002846019],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.001844862,"threshold_uncertainty_score":0.007886827,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.01592681096580529,"score_gpt":0.2789838467585548,"score_spread":0.2630570357927495,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}